$LONA News

Citizens Upgrades LeonaBio to Market Outperform, Announces $18 Price Target

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

Piper Sandler Initiates Coverage On LeonaBio with Overweight Rating, Announces Price Target of $20

LeonaBio (NASDAQ:LONA) Beats Q1 Loss Estimates as Phase 3 Breast Cancer Trial Enrollment Expands

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

LeonaBio Q1 EPS $(1.73) Beats $(2.50) Estimate

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.

LeonaBio, Inc. (LONA) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene Transcript

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

LeonaBio Q4 EPS $(2.77) Misses $(0.84) Estimate

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

LeonaBio Files Prospectus For Offering Up To 58.5M Shares For Potential Sale By Selling Stockholders

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer - Slideshow

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Athira Pharma Announces Reverse Stock Split

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update